We are live on ! Find out more
OTLK icon

Outlook Therapeutics

64 hedge funds and large institutions have $46.1M invested in Outlook Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 14

58% more capital inflows, than outflows

Capital inflows: $6.02M | Capital outflows: $3.81M

2% more funds holding

Funds holding: 63 → 64 (+1)

0.56% more ownership

Funds ownership: 11.66% → 12.22% (+0.56%)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

Holders
64
Holders Change
+1
Holders Change %
+1.59%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
25
Reduced
14
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OTLK Hedge Fund Activity: Q3 2021 in Review

64 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2021, worth a combined $46.1M — down 8.5% from $50.4M a quarter earlier.

Fund positioning in OTLK was balanced in Q3 2021: 8 funds opened new positions, 8 closed out, 25 added to existing stakes and 14 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.32M. The largest seller was Two Sigma Investments, cutting an estimated $1.49M.

  • 64 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2021, up from 63 in Q2 2021.
  • Funds reported $46.1M of Outlook Therapeutics stock for Q3 2021, down 8.5% quarter-over-quarter.
  • 8 funds opened new Outlook Therapeutics positions in Q3 2021 and 8 closed out, a net change of 0 holders.
  • The largest Outlook Therapeutics buyer in Q3 2021 was Millennium Management, an estimated $2.32M added.
  • The largest Outlook Therapeutics seller in Q3 2021 was Two Sigma Investments, an estimated $1.49M sold.

Based on aggregated 13F filings for Q3 2021.